We are live on
!
Find out more
Two Sigma Investments Portfolio holdings
AUM
$124B
1-Year Est. Return
33.93%
This Fund
S&P 500
This Quarter
Est. Return
+9.67%
1 Year Est. Return
+33.93%
3 Year Est. Return
+96.56%
5 Year Est. Return
+105.93%
10 Year Est. Return
+538.88%
AUM
$42.6B
AUM Growth
-$927M
(-2.1%)
Cap. Flow
-$4.42B
Cap. Flow
% of AUM
-10.38%
Top 10 Holdings %
Top 10 Hldgs %
9.02%
Holding
3,518
New
408
Increased
1,022
Reduced
1,392
Closed
532
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$244M |
| 2 |
Pfizer
PFE
|
+$234M |
| 3 |
Nike
NKE
|
+$201M |
| 4 |
Tesla
TSLA
|
+$200M |
| 5 |
S&P Global
SPGI
|
+$196M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$305M |
| 2 |
Advanced Micro Devices
AMD
|
+$241M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$231M |
| 4 |
Merck
MRK
|
+$199M |
| 5 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.1% |
| 2 | Healthcare | 11.63% |
| 3 | Consumer Discretionary | 11.09% |
| 4 | Financials | 10.76% |
| 5 | Industrials | 9.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2801
PetMed Express
PETS
$42.3M
| $90.7K | ﹤0.01% |
18,925
-136,156
| -88% | -$792K |
|
|
MAPS
2802
DELISTED
WM TECHNOLOGY INC A
MAPS
| $89.7K | ﹤0.01% |
+67,441
| New | +$62.5K |
|
2803
Cytek Biosciences
CTKB
$546M
| $88.6K | ﹤0.01% |
+13,211
| New | +$104K |
|
|
AVPTW
2804
DELISTED
AvePoint Inc Warrant
AVPTW
| $87.5K | ﹤0.01% |
91,800
| – | – |
|
2805
XBiotech
XBIT
$69.2M
| $87K | ﹤0.01% |
10,707
-14,733
| -58% | -$84.4K |
|
|
VXRT
2806
DELISTED
Vaxart
VXRT
| $84.6K | ﹤0.01% |
65,108
+13,338
| +26% | +$14K |
|
|
PHLT
2807
DELISTED
Performant Healthcare Inc
PHLT
| $84.4K | ﹤0.01% |
28,724
+914
| +3% | +$2.61K |
|
2808
Rafael Holdings
RFL
$107M
| $84.4K | ﹤0.01% |
49,771
| – | – |
|
2809
Axogen
AXGN
$2.5B
| $82.8K | ﹤0.01% |
+10,262
| New | +$91.9K |
|
2810
Cellectar Biosciences
CLRB
$20.5M
| $80.5K | ﹤0.01% |
+674
| New | +$73K |
|
2811
Humacyte
HUMA
$194M
| $79.7K | ﹤0.01% |
25,628
-307,048
| -92% | -$1.03M |
|
2812
Protara Therapeutics
TARA
$232M
| $79.2K | ﹤0.01% |
19,748
-5,397
| -21% | -$17.4K |
|
2813
Creative Medical Technology
CELZ
$9.21M
| $77.6K | ﹤0.01% |
+14,898
| New | +$69.3K |
|
|
CONN
2814
DELISTED
Conn's Inc.
CONN
| $76.3K | ﹤0.01% |
22,771
-26,533
| -54% | -$114K |
|
2815
Hyperfine
HYPR
$101M
| $76.1K | ﹤0.01% |
76,119
-33,263
| -30% | -$35.8K |
|
|
TEAD
2816
Teads Holding Co
TEAD
$67.7M
| $73.2K | ﹤0.01% |
18,533
-17,251
| -48% | -$69K |
|
2817
MeiraGTx Holdings
MGTX
$1.21B
| $72.8K | ﹤0.01% |
12,000
-100
| -0.8% | -$632 |
|
2818
Laird Superfood
LSF
$47.8M
| $72.7K | ﹤0.01% |
+30,297
| New | +$36.9K |
|
|
AMPS
2819
DELISTED
Altus Power
AMPS
| $72.7K | ﹤0.01% |
15,200
-35,800
| -70% | -$213K |
|
2820
Rekor Systems
REKR
$91.7M
| $71.9K | ﹤0.01% |
31,406
+2,206
| +8% | +$6.08K |
|
2821
Immix Biopharma
IMMX
$692M
| $70.2K | ﹤0.01% |
+22,862
| New | +$88.5K |
|
|
EMKR
2822
DELISTED
Emcore Corp
EMKR
| $69.3K | ﹤0.01% |
20,100
-8,797
| -30% | -$41.5K |
|
2823
Goldgroup Mining Inc.
GORO
$191M
| $68.8K | ﹤0.01% |
158,385
-7,200
| -4% | -$2.2K |
|
2824
Biote Corp
BTMD
$44.9M
| $68.3K | ﹤0.01% |
+11,773
| New | +$59K |
|
2825
Scilex Holding
SCLX
$48.9M
| $67.7K | ﹤0.01% |
1,217
| – | – |
|
Similar funds
VAM
Two Sigma Investments's Q1 2024 Portfolio in Review
As of Q1 2024, Two Sigma Investments held 3,518 positions worth $42.6B, down 2.1% from $43.5B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Two Sigma Investments withdrew a net $4.42B in Q1 2024, closing 532 positions and reducing 1,392 holdings. Its most notable exit was Rivian, an estimated $158M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 18% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Two Sigma Investments opened a new position in Pfizer worth $234M.
- Two Sigma Investments's largest Q1 2024 buy was Pfizer: 8,419,014 shares worth $234M.
- Two Sigma Investments added most to Gilead Sciences in Q1 2024, an estimated $244M increase.
- Two Sigma Investments's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $305M.
- Two Sigma Investments fully exited Rivian in Q1 2024, selling an estimated $158M.
- Two Sigma Investments's ten largest holdings make up 9% of its $42.6B portfolio in Q1 2024.
- Two Sigma Investments opened 408 new positions and closed 532 in Q1 2024.
- Two Sigma Investments's portfolio value fell 2.1% quarter-over-quarter to $42.6B.
Based on Two Sigma Investments's 13F filing for Q1 2024, filed 15 May 2024.